Eric K Rowinsky
CIK 1318886 · Chief Medical Officer · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BIIB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
180 VARICK STREET, 6TH FLOOR
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIIB | Director | 25,844 | $253.24 | $6.54M | -$12.52M | 24 | 2026-06-11 |
| VSTM | Director | 54,666 | $10.04 | $548.6K | $7.7K | 12 | 2026-05-26 |
| FBIOP | Director | 68,797 | $16.02 | $1.10M | -$117.1K | 8 | 2024-01-03 |
| NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Director | 17,072 | $0.00 | $2 | $0 | 11 | 2018-02-22 |
| FBIO | Director | 23,333 | $1.94 | $45.3K | $0 | 2 | 2017-01-24 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | — | — | — | $0 | 3 | 2016-06-22 |
| STEMLINE THERAPEUTICS INC (STML) Delisted | Chief Medical Officer | 143,688 | — | — | -$479.5K | 6 | 2015-04-28 |
| Fortress Biotech, Inc. (CNDO) Delisted | Director | 150,000 | — | — | $0 | 4 | 2015-03-16 |
| NAVIDEA BIOPHARMACEUTICALS, INC. (NEOP) Delisted | Director | 15,000 | — | — | $38.2K | 2 | 2011-08-23 |
| Savara Inc (ANX) Delisted | Director | — | — | — | $0 | 4 | 2010-07-01 |
| IMCLONE SYSTEMS INC (IMCL) Delisted | SVP, Chief Medical Officer | 0 | — | — | $0 | 4 | 2008-11-24 |
Recent Filings · Page 8 of 9
82 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-06-02 | BIIB | Grant (A) | +2,900 | $0 | EDGAR |
| 2010-07-01 | Savara Inc (ANX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-06-10 | BIIB | Grant (A) | +5,735 | $0 | EDGAR |
| 2010-03-24 | BIIB | Grant (A) | +500 | $0 | EDGAR |
| 2010-02-03 | Savara Inc (ANX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-11-26 | — | Disp (D) | — | $0 | |
| 2008-11-24 | IMCLONE SYSTEMS INC (IMCL) Delisted | U | −3,024 | -$211.7K | EDGAR |
| 2008-07-02 | Savara Inc (ANX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-03-25 | Savara Inc (ANX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-02-20 | IMCLONE SYSTEMS INC (IMCL) Delisted | Mixed | +1,774 | -$34.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.